🇺🇸 Aralast NP in United States

488 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 488

Most-reported reactions

1. Death — 117 reports (23.98%)
2. Pneumonia — 103 reports (21.11%)
3. Dyspnoea — 77 reports (15.78%)
4. Malaise — 32 reports (6.56%)
5. Chronic Obstructive Pulmonary Disease — 31 reports (6.35%)
6. Cough — 28 reports (5.74%)
7. Bronchitis — 27 reports (5.53%)
8. Headache — 26 reports (5.33%)
9. Fatigue — 25 reports (5.12%)
10. Fall — 22 reports (4.51%)

Source database →

Frequently asked questions

Is Aralast NP approved in United States?

Aralast NP does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Aralast NP in United States?

National Institute of Allergy and Infectious Diseases (NIAID) is the originator. The local marketing authorisation holder may differ — check the official source linked above.